newdrugapprovals.org
Sonepcizumab/LT1009-US-based Lpath has begun patient dosing in Phase 2a single-arm trial of anti-cancer drug, Asonep.
READ AT Study of ASONEP (Sonepcizumab/LT1009) to Treat Advanced Solid Tumors